Funded research projects
Principal investigators (PI) for the projects and titles listed below
- BIMID Project (PI: Sylvain DUBUCQUOI, U1286): characteristics and role of B lymphocytes in the pathophysiology of immune-mediated inflammatory diseases and their complications (infection and fibrosis): identification of biomarkers and therapeutic targets
- Vector-borne diseases project (PI: Agustin ROLANDELLI, CIIL, INSERM U1019, CNRS UMR9017): biological determinants of the physiology and transmission of pathogens in fleas. (cross-cutting project WP1 and WP3)
- MULTIPATH Project (PI: Vincent SOBANSKI, U1286): endotyping of inflammatory diseases using multidimensional integrative analysis: from health data to pathogenic mechanisms
- VATFIB Project (PI: Silvia SPECA, U1286): dysfunction of visceral adipose tissue: a new hallmark of progressive fibrosis associated with inflammatory and metabolic disorders
- Vector-borne diseases project (PI: Agustin ROLANDELLI, CIIL, INSERM U1019, CNRS UMR9017): biological determinants of the physiology and transmission of pathogens in fleas. (cross-cutting project WP1 and WP3)
- BradyKill project (PI: Mathieu GISSOT, CIIL): discovery of new molecules capable of eliminating the latent forms of the Toxoplasma gondii parasite
- ERAP-RES Project (PI: Rebecca DEPREZ-POULAIN, U1177 in collaboration with U1286): proof of concept for ERAP inhibition to overcome resistance in autoimmune diseases
- MyCyclo (PI: Arnaud MACHELART, CIIL): exploration of the potential of polymer-β-cyclodextrin nanocarriers for targeted treatment against Mycobacterium tuberculosis
- PANORAMICS (PI: Xavier DEZITTER, U1286): positive modulators of the purinergic P2RX7 receptor for the treatment of pulmonary fibrosis
- RIPKinh (PI: Natascha LELEU-CHAVAIN, U1286): development of NOD1-RIPK2 inhibitors for the treatment of chronic inflammatory bowel diseases
- TITAN (PI: Laurye VAN MAELE, CIIL): targeting the interleukin-23 pathway as an innovative treatment for antibiotic-resistant bacterial pneumonia
- TRIS TB (PI: Baptiste VILLEMAGNE, U1177-CIIL): development of tricyclic pirolactams for in vivo proof-of-concept of Mycobacterium tuberculosis Ndh-2 inhibition
- WANTED (PI: Nicolas WILLAND, U1177): design, synthesis and biological evaluation of new leads targeting the divisome
